Brief: Adverum Biotechnologies Completes Enrollment Of Phase 2 Luna Trial In Wet AMD

Adverum Biotechnologies

10/08/2023 21:16

Aug 10 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES COMPLETES ENROLLMENT OF PHASE 2
LUNA
TRIAL IN WET AMD AND REPORTS SECOND QUARTER 2023 FINANCIAL
RESULTS
    * ADVERUM BIOTECHNOLOGIES INC - CASH RUNWAY PROJECTED INTO
2025
    * ADVERUM BIOTECHNOLOGIES INC - LUNA 14-WEEK DATA ON
AFLIBERCEPT
PROTEIN LEVELS ANTICIPATED IN Q3 OF 2023
    * ADVERUM BIOTECHNOLOGIES INC - LUNA PRELIMINARY EFFICACY
AND
SAFETY DATA ANTICIPATED IN Q4 OF 2023
    * ADVERUM BIOTECHNOLOGIES INC- QTRLY NET LOSS WAS $31.5
MILLION,
OR $0.31 PER BASIC AND DILUTED SHARE

Source text for Eikon:  ID:nGNXc74Jkb 
Further company coverage:  ADVM.O 

 ((Reuters.Briefs@thomsonreuters.com;))